GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Stevanato Group SPA (NYSE:STVN) » Definitions » COGS-to-Revenue

Stevanato Group SPA (Stevanato Group SPA) COGS-to-Revenue : 0.74 (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Stevanato Group SPA COGS-to-Revenue?

Stevanato Group SPA's Cost of Goods Sold for the three months ended in Mar. 2024 was $189 Mil. Its Revenue for the three months ended in Mar. 2024 was $257 Mil.

Stevanato Group SPA's COGS to Revenue for the three months ended in Mar. 2024 was 0.74.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Stevanato Group SPA's Gross Margin % for the three months ended in Mar. 2024 was 26.36%.


Stevanato Group SPA COGS-to-Revenue Historical Data

The historical data trend for Stevanato Group SPA's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Stevanato Group SPA COGS-to-Revenue Chart

Stevanato Group SPA Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
COGS-to-Revenue
Get a 7-Day Free Trial 0.74 0.71 0.69 0.67 0.69

Stevanato Group SPA Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.68 0.69 0.69 0.68 0.74

Stevanato Group SPA COGS-to-Revenue Calculation

Stevanato Group SPA's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=812.934 / 1183.592
=0.69

Stevanato Group SPA's COGS to Revenue for the quarter that ended in Mar. 2024 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=188.91 / 256.515
=0.74

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Stevanato Group SPA  (NYSE:STVN) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Stevanato Group SPA's Gross Margin % for the three months ended in Mar. 2024 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 188.91 / 256.515
=26.36 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.


Stevanato Group SPA COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Stevanato Group SPA's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Stevanato Group SPA (Stevanato Group SPA) Business Description

Traded in Other Exchanges
Address
Via Molinella 17, Piombino Dese, Padua, ITA, 35017
Stevanato Group SPA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. Stevanato's revenue is geographically diversified, with 60% of sales from Europe, the Middle East and Africa (EMEA), 27% in North America, 10% in Asia-Pacific (APAC), and 3% from South America. It has two segments Biopharmaceutical and Diagnostic Solutions and Engineering.

Stevanato Group SPA (Stevanato Group SPA) Headlines